◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Peptide · Injectable NOT-RELEVANT HIGH

Tirzepatide

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict NOT-RELEVANT HIGH

For this user specifically — at 6'0-6'1, 185-190 lb, 10+ hr/wk MMA training, no metabolic indication — tirzepatide is medically wrong-fit, not bad. Strong appetite suppression directly counters MMA fueling needs; class-average ~25-40% lean-mass-loss fraction is incompatible with combat sport requiring muscle preservation; no cognitive upside; no indication exists. Distinct from semaglutide's SKIP-FOR-NOW because tirzepatide is even more potent (superior in head-to-head SURMOUNT-5), making lean-mass risk arithmetically larger per kg lost. The drug itself is best-in-class for T2D + obesity and now leads on OSA — verdict for those populations is STRONG-CANDIDATE. File entry exists for wiki completeness, not for this archetype's typical stack.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, high cognitive workload, athletic (this-archetype)
    NOT-RELEVANT

    No metabolic indication, no obesity, no T2D, no OSA. Appetite suppression undermines training fueling; lean-mass loss undermines MMA performance; no cognitive upside; CV/dementia signals apply to high-risk populations he isn't in. *This is the the user verdict, not the drug's verdict.* Verdict only re-opens with substantial physiology change (post-MMA-career weight gain to BMI ≥30, T2D diagnosis, OSA development, established CV disease).

  • 30-50, executive maintenance, mild metabolic creep (BMI 25-29, sedentary cognitive worker)
    OPTIONAL-ADD

    if BMI ≥27 with comorbidity. Zepbound approved for this range; benefit-risk reasonable. Tirzepatide is the more potent option vs. semaglutide; retatrutide will be more potent still post-2027 approval.

  • 30-50, metabolic syndrome / overweight (BMI 30+) / T2D
    STRONG-CANDIDATE

    currently best-validated weight-effective option. SURMOUNT-5 head-to-head superiority over semaglutide; SURPASS-2 head-to-head superiority on T2D endpoints. Genuine A-tier pick until retatrutide approval shifts the landscape.

  • 50+, mild cognitive decline
    WATCH-LIST

    No tirzepatide-specific cognitive trials yet; semaglutide's evoke trials will determine whether GLP-1 arm carries cognitive benefit; tirzepatide-specific extrapolation likely.

  • Anxiety-prone
    NEUTRAL

    GLP-1 class showing reward-modulation signals, possibly anxiolytic indirectly; not primary indication.

  • High athletic load, tested status (any combat sport, endurance, strength)
    SKIP

    (analogous to the user reasoning — caloric deficit + lean-mass risk; WADA status currently legal but always re-check class status before competition).

  • Sleep-disordered (OSA + obesity)
    STRONG-CANDIDATE

    first-line FDA-indicated class. Zepbound is the only GLP-1 / GIP class drug currently FDA-approved for OSA (Dec 2024); SURMOUNT-OSA established the indication. 51.5% AHI remission rate is genuinely class-leading.

  • Recovery-focused (post-injury, post-illness)
    CASE-BY-CASE

    If obesity is the recovery limiter, candidate. If anabolic recovery is the goal, not a fit.

  • Strength/anabolic-focused
    SKIP

    Goal mismatch — caloric deficit + lean-mass risk oppose hypertrophy. Address adipose with diet first; only if diet alone fails AND meaningful adipose burden exists does this class become relevant.

  • Older with cardiometabolic risk (60+, prior CV event, BMI ≥27)
    STRONG-CANDIDATE

    pending SURPASS-CVOT readout (2026-2027) for CV outcomes evidence. Until that readout, semaglutide retains uniquely strong CV outcomes evidence (SELECT) for non-diabetic obesity + established CV disease. Tirzepatide is the more weight-effective option but CV-outcomes evidence is one trial behind.

  • HFpEF + obesity
    STRONG-CANDIDATE

    SUMMIT (NEJM 2024) established 38% HF event reduction. Strong evidence in this niche.

  • MASH/MASLD (biopsy-confirmed)
    STRONG-CANDIDATE

    pending Phase 3 SYNERGY-NASH-2. Phase 2 showed 51-62% MASH resolution; competitive with retatrutide's liver-fat reduction though lower magnitude.

  • CKD + T2D
    OPTIONAL-ADD

    pending dedicated renal outcomes trial. Semaglutide has FLOW; tirzepatide does not yet.

  • Alcohol use disorder
    WATCH-LIST

    Following semaglutide AUD trial program by ~2 years.

▸ Subjective experience (deep)
  • Onset: Appetite suppression typically begins within 24-72 hr of first injection; "food noise" silencing reported within first week. Weight loss begins gradually as titration progresses.
  • Peak effect: Maximal suppression at maintenance dose (10, 12.5, or 15 mg weekly for obesity; 5-15 mg for T2D). Plateau after 12-18 months for most users; SURMOUNT-3 lead-in cohort showed continued loss past 18 months.
  • Energy: Variable. Some report mild thermogenic feel and clearer cognition (likely from improved metabolic state in formerly obese users); others report fatigue from net caloric deficit, especially during titration. GIP arm may modestly support energy during deficit vs. semaglutide-only experience.
  • GI: Nausea (~25-30% in SURMOUNT-1 vs. ~40% in semaglutide STEP-1 — tirzepatide modestly better tolerability), vomiting (~10%), diarrhea (~21%), constipation (~17%). Most pronounced in days after each dose escalation. Eating slowly, smaller portions, low-fat meals, ginger, OTC ondansetron-equivalents help. Tolerability generally reported as better than semaglutide at comparable weight-loss intensity.
  • Cognitive: Generally preserved; no dedicated cognitive trials in healthy adults. Dementia-prevention signals are hypothesis-stage.
  • Mood: Mixed. Reduced food-reward circuitry may blunt general reward sensitivity in some users; others report improved mood from physique changes. No confirmed suicidality signal (analogous to semaglutide's resolved 2023 signal).
  • Sulfur burps + reflux: reported by ~10-15% of community users; less prominent than semaglutide reports anecdotally
  • Hair shedding: telogen effluvium from rapid caloric deficit; not drug-specific
▸ Tolerance + cycling deep dive
  • Tolerance: Modest pharmacodynamic tolerance to GI motility effects (nausea fades over weeks at stable dose). No meaningful tolerance to weight-loss efficacy at maintenance dose during trials up to 88 weeks (SURMOUNT-4).
  • Cycling: Not cycled. The drug is intended for chronic / lifelong use. Discontinuation produces ~14% regain at 52 weeks per SURMOUNT-4 (lower than semaglutide's STEP-4 ~67% regain figure due to different trial designs — SURMOUNT-4 only randomized after 36-week lead-in, so absolute regain depends on baseline). Class-wide pattern: substantial regain off-drug.
  • Maintenance dose research: SURMOUNT-4 demonstrated continued use sustains loss; no validated low-dose-maintenance protocol comparable to retatrutide's 2026 readout.
▸ Stacking deep dive

Synergistic with

  • Resistance training + 1.6-2.2 g/kg/day protein: essential adjunct to preserve lean mass. Not optional for any user, especially athletes.
  • Creatine 5 g/day: lean-mass preservation in caloric deficit
  • B-complex vitamins: support metabolic flux, counter potential micronutrient gaps from reduced intake
  • Vitamin D3 + K2: supports bone density during rapid weight loss (GIP arm may be partly bone-protective but adjunct still wise)
  • Magnesium glycinate / threonate: GI symptom management + electrolyte balance during nausea/diarrhea phases
  • Omega-3 (DHA/EPA): anti-inflammatory adjunct
  • Statins: typically additive on lipid panel improvements
  • SGLT2 inhibitors (in T2D): complementary glycemic + cardiovascular + renal mechanisms; common dual-prescribing pattern in modern T2D management

Avoid stacking with

  • Other GLP-1 / GIP / glucagon agonists (semaglutide, retatrutide, liraglutide, exenatide, dulaglutide): redundant target, multiplicative GI toxicity, no additional efficacy ceiling. Pick one.
  • Insulin / sulfonylureas without dose reduction: hypoglycemia risk
  • Other agents with delayed gastric emptying (anticholinergics, opioids): compounds GI burden
  • Anabolic steroids / SARMs in non-medical contexts: the conceptual mismatch — using a catabolic-leaning agent simultaneously with anabolic agents — flags confused goals
  • Pre-procedure / pre-anesthesia: hold ≥1 week before elective sedation procedures (aspiration risk)

Neutral / safe co-administration

  • Most CNS nootropics (modafinil, racetams, citicoline, etc.) — no direct interaction
  • Most antihypertensives (BP often drops, may need dose reduction)
  • Antidepressants — generally fine; bupropion may help offset reward-blunting if it occurs
  • Most non-anabolic supplements (the canonical stack components are all compatible — but the question is moot since the drug isn't recommended)
▸ Drug interactions deep dive
  • Delayed gastric emptying affects oral drug absorption — narrow-therapeutic-index oral drugs (warfarin, levothyroxine, NTI antibiotics) may need timing adjustment or monitoring
  • Oral contraceptives: tirzepatide labeling specifically warns of reduced exposure → contraceptive failure risk. Switch to non-oral method (IUD, implant, injection) or add barrier method during initiation and 4 weeks after each dose escalation. More definitively flagged on tirzepatide than semaglutide.
  • No significant CYP induction/inhibition at therapeutic doses (peptide drug, not metabolized via CYP)
  • Insulin / sulfonylureas: dose reduction usually needed to avoid hypoglycemia
  • Levothyroxine: absorption variability; monitor TSH after 4-6 weeks of stable dose
▸ Pharmacogenomics
  • GLP1R rs6923761 (Gly168Ser, MAF ~29% in White Europeans):
    • A allele (variant Ser): lower glycemic response to GLP-1 agonists (HbA1c reduction ~0.08% less per allele, p=6.0×10⁻⁵), but greater weight loss response and greater delay in gastric emptying
    • G allele (common Gly): stronger glycemic response, weaker weight-loss differential
    • For tirzepatide specifically: emerging dual-agonist PGx (PMC12473131, 2025) suggests partially independent variant effects on GLP-1 vs. GIP arms.
  • GIPR variants (rs1800437 E354Q, others): Less characterized but actively being investigated for tirzepatide-specific response. Some signal that GIPR loss-of-function variants may modulate response to the GIP arm differentially from GLP-1.
  • For the user: relevant on 23andMe results (~June 2026) for completeness; predicts response if he ever needed this class. Does not change NOT-RELEVANT verdict.
  • Practical takeaway: No actionable PGx for prescribing decisions in 2026 outside research settings. Effect sizes too small for clinical individualization.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx, Zepbound (obesity) — pens Pharmacy via prescription $1,059/mo retail; $0-200/mo with insurance + indication Highest BMI ≥30 (or ≥27 + comorbidity) required for coverage; OSA indication added Dec 2024 helps coverage
US Rx, Zepbound (obesity) — single-dose vials LillyDirect direct-to-consumer ~$349/mo (2.5 mg) up to ~$899/mo (15 mg); 5 mg vial ~$549/mo as of 2025 Highest Lilly's response to compounding pressure; cash-pay self-injection vials, no insurance involved
US Rx, Mounjaro (T2D) Pharmacy via prescription $1,069/mo retail; $25-200/mo with T2D-indicated insurance Highest T2D required; off-label weight-loss use largely insurance-blocked since Zepbound launched
Compounding pharmacy (US 503A/503B) Various $200-500/mo Low-Variable Compounding access has effectively closed for tirzepatide as of 2026. FDA declared the shortage resolved Oct 2, 2024. Enforcement-discretion period ended Feb 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities. April 30, 2026 — FDA proposed excluding tirzepatide from the 503B Bulks List entirely, citing no clinical need for outsourcing-facility compounding. Since September 2025 the FDA has issued 135+ warning letters to GLP-1 compounders and telehealth companies. Mass-compounded tirzepatide is now illegal; some 503A pharmacies continue under patient-specific medical-necessity claims (e.g., documented allergy to a brand-name excipient, non-standard dose), but this exists in a narrow regulatory grey zone and is not a viable mainstream sourcing path. Treat compounded tirzepatide as effectively unavailable as of mid-2026.
Telehealth Rx (Hims, Ro, Sequence, Mochi, Henry Meds, etc.) Various $200-1,500/mo depending on path Medium-high Some route through compounders (now restricted), others through retail Rx + LillyDirect. Read fine print.
Gray-market research peptide ("not for human consumption") Various peptide vendors $80-200/vial Low-medium Quality spread huge; HPLC verification advised; not recommended given Rx availability
India generic (early access, 2025-2026) Sun Pharma, Cipla, others ~$50-150/mo (when available; not US-legal import for personal use) Medium Lilly patent expiration in India 2024 enabled generic launch; quality variable; geographic + legal restrictions for US users
Manufacturer patient assistance Eli Lilly Cares Free (income-qualified) Highest Income limits apply; not realistic for most

For the user: sourcing is genuinely easy if he ever needed it (Zepbound via LillyDirect or telehealth Rx given documented BMI ≥27 + comorbidity; Mounjaro if T2D develops; OSA indication if it emerges). The verdict isn't "can't get it" — it's "no indication exists." Cost would not be the barrier.

▸ Biomarkers to track (deep)
  • Baseline (before starting):
    • Weight, BMI, waist circumference, BP, resting HR
    • HbA1c, fasting glucose, fasting insulin, HOMA-IR
    • Lipid panel: LDL-C, HDL-C, non-HDL-C, ApoB, triglycerides
    • ALT, AST, GGT
    • Lipase, amylase
    • eGFR, creatinine
    • Calcitonin (one-time, if MTC family history)
    • DEXA for body composition (lean vs. fat baseline)
    • Pregnancy test if applicable; reliable contraception confirmed (specifically — non-oral method during dose escalation)
    • AHI / sleep study if OSA suspected (and tracking the indication)
  • During use (months 1, 3, 6, 12, then annually):
    • Weight, BP, HR
    • HbA1c, lipid panel
    • ALT, AST
    • Lipase if abdominal symptoms
    • DEXA every 6 months to track lean-mass trajectory
    • AHI if OSA indication
  • Post-cycle / discontinuation:
    • Weight at 4, 8, 12 weeks then quarterly to track regain trajectory
    • HbA1c, lipids at 3-6 months
    • Plan for behavioral / dietary continuation strategy
▸ Controversies / open debates Live debate
  1. Muscle-loss debate. Lean-mass loss as fraction of total weight loss runs ~25-40% across studies. TCTMD viewpoint (2024) argues "don't worry about it" — losing weight as obese is net-positive even with some lean loss. Counter-argument: meaningful for older patients at sarcopenia risk and for any athlete. Resolution: protein adequacy (1.6-2.2 g/kg/day) + resistance training reliably attenuates the effect; most clinical trials don't enforce these adjuncts. For the user: the resolution doesn't apply — he isn't choosing between "lose weight on tirzepatide vs. don't" because he doesn't need to lose weight at all. Lean loss is pure downside. Tirzepatide's superior potency means more absolute lean-mass loss per cycle vs. semaglutide.
  2. Long-term safety. Class has been around since 2005 (exenatide); tirzepatide approved 2022; longest exposures ~4-5 years at therapeutic doses. Boxed warning for thyroid C-cell tumors based on rat data with no human confirmation in 4+ years of broad use. Shorter post-marketing horizon than semaglutide; ongoing surveillance.
  3. Rebound weight regain. Class-wide pattern. SURMOUNT-4 showed ~14% regain at 52 weeks of placebo (after lead-in) — magnitude depends on trial design. Real efficacy is conditional on lifelong use OR successful behavioral transition.
  4. Aesthetic / off-label use in non-obese populations. Tirzepatide adopted enthusiastically by people in normal-weight or overweight (BMI 25-29) ranges for "vanity 10 lb" or athletic cutting purposes. Risk profile is different: reduced upside (less adipose to mobilize), same downside (lean loss, GI, cardiovascular signals). Tirzepatide's superior potency makes off-label use riskier, not safer. This is exactly the misuse pattern a user in this archetype should avoid even though the temptation will exist as the drug remains culturally ubiquitous.
  5. GIP receptor agonism vs. antagonism debate. Maridebart cafraglutide (MariTide, Amgen) is a GLP-1 agonist + GIP antagonist showing comparable weight loss in Phase 2. Mechanistically opposite GIP arm vs. tirzepatide. Active scientific debate about whether GIP agonism or antagonism is the right adjunct to GLP-1; both produce weight loss; mechanism not fully resolved.
  6. vs. semaglutide head-to-head (SURMOUNT-5, 2024): tirzepatide clearly superior on weight loss (~20% vs. ~14% in head-to-head). Tirzepatide is now the more weight-effective option in the class; semaglutide retains uniquely strong CV outcomes evidence (SELECT) until SURPASS-CVOT reads out.
  7. vs. retatrutide (no head-to-head yet): retatrutide Phase 2 showed ~24% at 12 mg, Phase 3 TRIUMPH-4 showed ~28.7%; retatrutide's triple-target profile produces larger weight loss in indirect comparison. Retatrutide approval expected late 2027 / early 2028 will likely shift class-leading status.
  8. Compounding pharmacy access timing. FDA declared tirzepatide shortage resolved October 2024, after which 503A compounding for tirzepatide became technically non-compliant. Compounding access has tightened substantially through 2025; Lilly's LillyDirect single-dose vials were specifically introduced as the legal cash-pay alternative. Treat current compounding access as restricted.
  9. Health equity. Cost + insurance gating creates two-tier metabolic-health access; broader concern for the class but Lilly's LillyDirect direct-to-consumer pricing partially addresses it.
  10. Hypothesized GIP arm benefits in bone, brain, mood. Pre-clinical and early clinical signals exist for GIP-R-mediated effects on bone density, neuroinflammation, and reward processing. None established at trial-level evidence yet.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: NOT-RELEVANT for users in this archetype-archetype (HIGH confidence). Rationale: at 6'0-6'1, 185-190 lb, no metabolic disease, no obesity, no T2D, no OSA, and an active MMA career, there is no indication for the drug. Weight + sport + brain-priority profile makes the drug medically wrong-fit, not bad. Verdict distinct from semaglutide's SKIP-FOR-NOW because (a) tirzepatide is more potent, magnifying the lean-mass downside, and (b) "NOT-RELEVANT" better captures the absence of any current indication for someone in the user's physiology vs. semaglutide's "wrong-fit but recognizable scenarios in which it could become relevant." STRONG-CANDIDATE for the populations the drug is designed for (T2D, obesity at BMI ≥27, OSA + obesity, HFpEF + obesity, MASH/MASLD). File entry exists for wiki completeness; verdict would change with substantial physiology change.
▸ Open questions / gaps Open
  1. SURPASS-CVOT readout (2026-2027): does tirzepatide match semaglutide's SELECT-grade CV evidence? If yes, tirzepatide becomes class-leading on CV outcomes too.
  2. SYNERGY-NASH-2 Phase 3 readout (2026-2027): does Phase 2 MASH resolution rate (51-62%) hold in Phase 3?
  3. GIP receptor pharmacogenomics: dual-agonist response variation by GIPR variant; emerging research, not yet actionable.
  4. Long-term (10+ yr) safety surveillance: thyroid C-cell signal, gastroparesis persistence quantification.
  5. Lean-mass preservation under matched protein + resistance training: no rigorously-controlled head-to-head trial conducted; would inform athletic-population decision-making.
  6. Maintenance dose strategies post-loss: can lower doses (5 mg, 7.5 mg) hold 15 mg-induced weight loss?
  7. Pediatric / adolescent use: less developed than semaglutide which has age 12+ Wegovy approval since 2022.
  8. GIP agonism vs. antagonism debate: which approach (tirzepatide-style GIP agonism vs. MariTide-style GIP antagonism) ultimately wins on long-term outcomes?
  9. For the user specifically: none. The verdict is robust to any plausible new data given his current physiology. Only physical-state change (sport retirement + significant adipose accumulation, OR cardiometabolic disease emergence, OR OSA development) would re-open the question.

References

SURMOUNT-2 (Garvey et al., Lancet 2023)

thelancet.com · 2023

01200-X/fulltext) — Phase 3 obesity + T2D, 14.7% weight loss

View Study

SURMOUNT-3 (Wadden et al., Nature Medicine 2023)

nature.com · 2023

Phase 3 obesity with intensive lifestyle lead-in

View Study

SURMOUNT-4 (Aronne et al., JAMA 2024)

jamanetwork.com · 2024

Phase 3 maintenance / withdrawal

View Study

Lancet Diabetes & Endo: GLP-1 PGx GWAS (2022)

thelancet.com · 2022

00340-0/fulltext) — GLP1R rs6923761 effect on response

View Study

PMC: Tirzepatide pharmacogenomics (2025)

pmc.ncbi.nlm.nih.gov · 2025

emerging dual-agonist PGx

View Study

SURPASS-2 (Frías et al., NEJM 2021)

nejm.org · 2021

Phase 3 head-to-head vs. semaglutide 1 mg in T2D

View Source

SURMOUNT-1 (Jastreboff et al., NEJM 2022)

nejm.org · 2022

Phase 3 obesity primary efficacy trial, 20.9% weight loss at 15 mg

View Source

SURMOUNT-5 head-to-head (Aronne et al., NEJM 2024)

nejm.org · 2024

Phase 3 head-to-head vs. semaglutide in obesity, 20.2% vs. 13.7% weight loss

View Source

SURMOUNT-OSA (Malhotra et al., NEJM 2024)

nejm.org · 2024

Phase 3 obstructive sleep apnea + obesity, established OSA indication

View Source

SUMMIT HFpEF (Packer et al., NEJM 2024)

nejm.org · 2024

HFpEF + obesity, 38% HF event reduction

View Source

Latest research

PPInteractions8 compounds▸
PeptideStatusNote
Semaglutide
Avoid CombinationBoth are GLP-1 agonists - combining increases hypoglycemia and severe GI side effect risk
Liraglutide
Avoid CombinationAnother GLP-1 agonist - dual therapy contraindicated due to additive effects
Insulin
Monitor CombinationMay require significant insulin dose reduction due to improved sensitivity and glucose control
Metformin
SynergisticComplementary mechanisms for diabetes management and weight loss with enhanced efficacy
CJC-1295
CompatibleGrowth hormone support may help preserve muscle mass during rapid weight loss
Ipamorelin
CompatibleMay help maintain metabolic rate and muscle preservation during caloric restriction
BPC-157
CompatibleNo known interactions, may support gut health and reduce GI side effects
5-Amino-1MQ
CompatibleNNMT inhibition may complement GLP-1 effects for enhanced metabolic optimization
Source: pep-pedia.org
PP Community insights — click to load ▸
Imported from pep-pedia.org. Compounds with the PP badge use community-survey data captured from pep-pedia, who run a longer-running poll with a much larger respondent base than ours yet. Refreshed every ~6h. Our own writable poll is below for new data we collect directly.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…